IDEXX Laboratories (IDXX) Given Daily News Sentiment Score of 0.36
News headlines about IDEXX Laboratories (NASDAQ:IDXX) have been trending positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.36 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 33 out of 100, indicating that recent press coverage is unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Northcoast Research Equities Analysts Lower Earnings Estimates for IDEXX Laboratories, Inc. (NASDAQ:IDXX) (americanbankingnews.com)
- IDEXX Laboratories, Inc. (IDXX) to Post Q3 2017 Earnings of $0.74 Per Share, William Blair Forecasts (americanbankingnews.com)
- Challenges And Opportunities For IDEXX Laboratories, Inc. (IDXX), Impax Laboratories, Inc. (IPXL) – AllStockNews (allstocknews.com)
- IDEXX Laboratories, Inc.’s Investors Look the Gift Horse in the Mouth … – Madison.com (host.madison.com)
- IDEXX Laboratories Inc Reveals 27% Rise In Q2 Earnings (nasdaq.com)
A number of research analysts have weighed in on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research note on Wednesday. BidaskClub lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday. CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target on the stock in a research report on Friday, July 28th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price target on the stock in a research report on Wednesday, July 19th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $173.80.
IDEXX Laboratories (IDXX) traded up 1.90% during mid-day trading on Thursday, reaching $154.09. 758,860 shares of the company traded hands. The stock has a 50-day moving average of $163.95 and a 200 day moving average of $154.43. IDEXX Laboratories has a 52-week low of $102.45 and a 52-week high of $173.01. The stock has a market capitalization of $13.45 billion, a PE ratio of 52.95 and a beta of 0.49.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 595.57%. The company had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. During the same period in the prior year, the company posted $0.74 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. Equities research analysts expect that IDEXX Laboratories will post $3.07 earnings per share for the current year.
IDEXX Laboratories declared that its board has initiated a share repurchase plan on Wednesday, May 3rd that allows the company to buyback 3,000,000 outstanding shares. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.
In related news, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $167.82, for a total value of $2,181,660.00. Following the sale, the chairman now directly owns 1,032,994 shares in the company, valued at approximately $173,357,053.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Giovani Twigge sold 2,572 shares of the stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $166.90, for a total transaction of $429,266.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 73,572 shares of company stock worth $11,992,167. Corporate insiders own 2.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/03/favorable-news-coverage-unlikely-to-impact-idexx-laboratories-idxx-stock-price-updated-updated-updated.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.